Drug Development

New Drug Targets Host Response to HIV

Published in AIDS Weekly, June 26th, 1995

A new drug inhibits HIV production by preventing host cells from responding to HIV signals.

The drug is 1-(11-octylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, or commonly known as CT-2576. CT-2576 inhibits HIV expression in U1 cells at a 50% inhibitory concentration (IC₅₀ ) of 1 (mu)M. An acetylated derivative of CT-2576, CT-3537, inhibits HIV expression at similar concentrations.

Because CT-2576 is targeted to the cells of an infected person and not to the virus itself, this approach should not give rise to the drug-resistant viral mutants that limit the efficacy of other antiretroviral agents.

"In view of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry